Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic
combination approach that omits or delays the use of chemotherapy in metastatic disease,
while improving efficacy and durability of response. The approach combines two potentially
effective and previously studied strategies: androgen receptor blockade and immune checkpoint
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborators:
Bristol-Myers Squibb Memorial Sloan Kettering Cancer Center